ArticleClinical journal of gastroenterology2026

Paradoxical hyperprogressive disease in MSI-high intrahepatic cholangiocarcinoma treated with pembrolizumab.

Takayuki Tanaka et al.PubMed ↗Publisher ↗

No numbers read from the abstract.